Cytostatic hypothermia and its impact on glioblastoma and survival.

Journal Article (Journal Article)

Patients with glioblastoma (GBM) have limited options and require novel approaches to treatment. Here, we studied and deployed nonfreezing "cytostatic" hypothermia to stunt GBM growth. This growth-halting method contrasts with ablative, cryogenic hypothermia that kills both neoplastic and infiltrated healthy tissue. We investigated degrees of hypothermia in vitro and identified a cytostatic window of 20° to 25°C. For some lines, 18 hours/day of cytostatic hypothermia was sufficient to halt division in vitro. Next, we fabricated an experimental tool to test local cytostatic hypothermia in two rodent GBM models. Hypothermia more than doubled median survival, and all rats that successfully received cytostatic hypothermia survived their study period. Unlike targeted therapeutics that are successful in preclinical models but fail in clinical trials, cytostatic hypothermia leverages fundamental physics that influences biology broadly. It is a previously unexplored approach that could provide an additional option to patients with GBM by halting tumor growth.

Full Text

Duke Authors

Cited Authors

  • Enam, SF; Kilic, CY; Huang, J; Kang, BJ; Chen, R; Tribble, CS; Ilich, E; Betancur, MI; Blocker, SJ; Owen, SJ; Buckley, AF; Lyon, JG; Bellamkonda, RV

Published Date

  • November 25, 2022

Published In

Volume / Issue

  • 8 / 47

Start / End Page

  • eabq4882 -

PubMed ID

  • 36427309

Pubmed Central ID

  • PMC9699673

Electronic International Standard Serial Number (EISSN)

  • 2375-2548

Digital Object Identifier (DOI)

  • 10.1126/sciadv.abq4882


  • eng

Conference Location

  • United States